Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
Background Immune-related adverse events (irAEs) are a serious side effect of immune checkpoint inhibitor (ICI) therapy for patients with advanced cancer. Currently, predisposing risk factors are undefined but understanding which patients are at increased risk for irAEs severe enough to require hosp...
Main Authors: | Kun-Hsing Yu, Shannon Wongvibulsin, William Murphy, Leyre Zubiri, Vartan Pahalyants, Mark Kalinich, Feicheng Wang, Vivek Naranbhai, Alexander Gusev, Kerry L Reynolds, Chenyue Lu, Shawn G Kwatra, Yevgeniy R Semenov |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/3/e001935.full |
Similar Items
-
854 Prediction of severe immune-related adverse events in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the United States
by: Kun-Hsing Yu, et al.
Published: (2020-11-01) -
855 Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
by: Shannon Wongvibulsin, et al.
Published: (2020-11-01) -
826 Risk of COVID-19 infection among patients receiving immune checkpoint inhibitor therapy: a tertiary care hospital system collaboration with the Massachusetts department of health
by: Vartan Pahalyants, et al.
Published: (2020-11-01) -
481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors
by: Michael Manos, et al.
Published: (2020-11-01) -
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
by: Michael S. Hughes, et al.
Published: (2019-09-01)